

Supplementary Material

Table S1. STROBE Statement-Checklist.

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	1, 2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
Methods			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2, 3
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	3
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	3
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3
Bias	9	Describe any efforts to address potential sources of bias	3
Study size	10	Explain how the study size was arrived at	2, 3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	3
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	3
		(b) Describe any methods used to examine subgroups and interactions	3
		(c) Explain how missing data were addressed	3
		(d) If applicable, describe analytical methods taking account of sampling strategy	2, 3
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study —e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	3
		(b) Give reasons for non-participation at each stage	3

		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	3, 4
		(b) Indicate number of participants with missing data for each variable of interest	-
Outcome data	15*	Report numbers of outcome events or summary measures	5-9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	5-9
		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	5-9
Discussion			
Key results	18	Summarise key results with reference to study objectives	10, 11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11, 12
Generalisability	21	Discuss the generalisability (external validity) of the study results	10, 11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for exposed and unexposed groups.

Supplementary material S2. Translated questionnaire.


Which is your Gender?			
<input type="checkbox"/> Male	<input type="checkbox"/> Female	<input type="checkbox"/> I prefer not to declare it	
What age group are you in?			
<input type="checkbox"/> From 20 to 35 years	<input type="checkbox"/> From 36 to 55 years	<input type="checkbox"/> From 56 to 75 years	<input type="checkbox"/> I prefer not to declare it
What kind of employee are you?			
<input type="checkbox"/> Healthcare workers	<input type="checkbox"/> Non-Healthcare workers	<input type="checkbox"/> I prefer not to declare it	
How long have you been employed by Central Tuscany Local Health Authority (CT-LHA)?			
<input type="checkbox"/> From 1 to 5 years	<input type="checkbox"/> From 6 to 15 years	<input type="checkbox"/> Over 15 years	<input type="checkbox"/> I prefer not to declare it

How many doses of COVID-19 vaccine did you receive?					
<input type="checkbox"/> None	<input type="checkbox"/> Only one	<input type="checkbox"/> Only two	<input type="checkbox"/> Three		
How much do you think the following reasons might influence your decision to undergo the booster dose for COVID-19?					
Fear of infection	<input type="checkbox"/> Very much	<input type="checkbox"/> Much	<input type="checkbox"/> Neither much nor little	<input type="checkbox"/> Little	<input type="checkbox"/> Very Little
Fear of infecting others	<input type="checkbox"/> Very much	<input type="checkbox"/> Much	<input type="checkbox"/> Neither much nor little	<input type="checkbox"/> Little	<input type="checkbox"/> Very Little
Obligation	<input type="checkbox"/> Very much	<input type="checkbox"/> Much	<input type="checkbox"/> Neither much nor little	<input type="checkbox"/> Little	<input type="checkbox"/> Very Little
Not having received the booster dose for COVID-19, how likely do you think it is to:					
Being infected	<input type="checkbox"/> Very much	<input type="checkbox"/> Much	<input type="checkbox"/> Neither much nor little	<input type="checkbox"/> Little	<input type="checkbox"/> Very Little
Infecting others	<input type="checkbox"/> Very much	<input type="checkbox"/> Much	<input type="checkbox"/> Neither much nor little	<input type="checkbox"/> Little	<input type="checkbox"/> Very Little
How do you assess the following aspects of the vaccine used in the COVID-19 campaign for the workers in CT-LHA?					
Efficacy	<input type="checkbox"/> Very High	<input type="checkbox"/> High	<input type="checkbox"/> Medium	<input type="checkbox"/> Low	<input type="checkbox"/> Very Low
Safety	<input type="checkbox"/> Very High	<input type="checkbox"/> High	<input type="checkbox"/> Medium	<input type="checkbox"/> Low	<input type="checkbox"/> Very Low
Why would you undergo the booster dose of COVID-19 vaccine?					
Effective	<input type="checkbox"/> Very High	<input type="checkbox"/> High	<input type="checkbox"/> Medium	<input type="checkbox"/> Low	<input type="checkbox"/> Very Low
Safe	<input type="checkbox"/> Very High	<input type="checkbox"/> High	<input type="checkbox"/> Medium	<input type="checkbox"/> Low	<input type="checkbox"/> Very Low
Updated	<input type="checkbox"/> Very High	<input type="checkbox"/> High	<input type="checkbox"/> Medium	<input type="checkbox"/> Low	<input type="checkbox"/> Very Low
Which type of COVID--19 vaccine would you choose for the booster dose?					
<input type="checkbox"/> mRNA	<input type="checkbox"/> Viral Vector	<input type="checkbox"/> mRNA updated	<input type="checkbox"/> Indifferent		
How do you assess the following aspects in the vaccination campaign for employees of CT-LHA?					
Quality of communication	<input type="checkbox"/> Very High	<input type="checkbox"/> High	<input type="checkbox"/> Medium	<input type="checkbox"/> Low	<input type="checkbox"/> Very Low
Ease of booking	<input type="checkbox"/> Very High	<input type="checkbox"/> High	<input type="checkbox"/> Medium	<input type="checkbox"/> Low	<input type="checkbox"/> Very Low
Ease of access to vaccination hubs	<input type="checkbox"/> Very High	<input type="checkbox"/> High	<input type="checkbox"/> Medium	<input type="checkbox"/> Low	<input type="checkbox"/> Very Low
From whom would you like to receive information on the technical and scientific aspects of the booster dose of the COVID--19 vaccine?					
<input type="checkbox"/> Corporate Task Force	<input type="checkbox"/> Occupational physician		<input type="checkbox"/> Ministry of Health Tutorial		
<input type="checkbox"/> General Practitioner	<input type="checkbox"/> Company Intranet		<input type="checkbox"/> Other		

From whom would you like to receive information regarding the logistic-organizational aspects of the COVID--19 booster dose?		
<input type="checkbox"/> Medical Direction	<input type="checkbox"/> Prevention Department	<input type="checkbox"/> Vaccination physicians
<input type="checkbox"/> Corporate Task Force	<input type="checkbox"/> Other	
What tools would you prefer for disseminating information on the booster dose of the COVID-19 vaccine?		
<input type="checkbox"/> Institutional e-mail	<input type="checkbox"/> WhatsApp	<input type="checkbox"/> Operating Procedures
<input type="checkbox"/> Internal circulars	<input type="checkbox"/> Other	

Supplementary material S3. Missing data analysis.

Analyses were carried out with R version 4.0.1 and the package “finalfit”. Chi-squared test was carried out to evaluate an association between missing/non missing data of the questionnaire item and the variable of interest. Missing are present only on 125 out of 2010 observations.



Here, chi-squared test results were reported:

Missing data analysis: Doses		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.440
	36-55	1050 (99.0)	11 (1.0)	
	56-75	803 (98.4)	13 (1.6)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1449 (98.9)	16 (1.1)	0.649
	M	477 (98.6)	7 (1.4)	
	N.D.	39 (100.0)		
Occupation	HCW	1375 (98.8)	16 (1.2)	0.751
	N-HCW	563 (98.6)	8 (1.4)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.639
	6-15	521 (98.7)	7 (1.3)	
	≥16	1317 (98.7)	17 (1.3)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Fear of Infection		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.692
	36-55	1052 (99.2)	9 (0.8)	
	56-75	807 (98.9)	9 (1.1)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1455 (99.3)	10 (0.7)	0.124
	M	476 (98.3)	8 (1.7)	
	N.D.	39 (100.0)		
Occupation	HCW	1376 (98.9)	15 (1.1)	0.438
	N-HCW	568 (99.5)	3 (0.5)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.683
	6-15	522 (98.9)	6 (1.1)	
	≥16	1322 (99.1)	12 (0.9)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Fear of Infecting Others		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.632
	36-55	1053 (99.2)	8 (0.8)	
	56-75	807 (98.9)	9 (1.1)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1457 (99.5)	8 (0.5)	0.052
	M	476 (98.3)	8 (1.7)	
	N.D.	39 (100.0)		
Occupation	HCW	1378 (99.1)	13 (0.9)	0.773
	N-HCW	567 (99.3)	4 (0.7)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.706

	6-15	524 (99.2)	4 (0.8)
	≥16	1321 (99.0)	13 (1.0)
	N.D.	22 (100.0)	0 (0.0)

Missing data analysis: Obligation		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.632
	36-55	1053 (99.2)	8 (0.8)	
	56-75	807 (98.9)	9 (1.1)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1456 (99.4)	9 (0.6)	0.083
	M	476 (98.3)	8 (1.7)	
	N.D.	39 (100.0)		
Occupation	HCW	1379 (99.1)	12 (0.9)	0.830
	N-HCW	567 (99.3)	4 (0.7)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.753
	6-15	523 (99.1)	5 (0.9)	
	≥16	1322 (99.1)	12 (0.9)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Being Infected		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.632
	36-55	1053 (99.2)	8 (0.8)	
	56-75	807 (98.9)	9 (1.1)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1455 (99.3)	10 (0.7)	0.420
	M	478 (98.8)	6 (1.2)	
	N.D.	39 (100.0)		
Occupation	HCW	1376 (98.9)	15 (1.1)	0.438
	N-HCW	568 (99.5)	3 (0.5)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.750
	6-15	524 (99.2)	4 (0.8)	
	≥16	1322 (99.1)	12 (0.9)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Infecting Others		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.587
	36-55	1049 (98.9)	12 (1.1)	
	56-75	810 (99.3)	6 (0.7)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1451 (99.0)	14 (1.0)	0.661
	M	481 (99.4)	3 (0.6)	
	N.D.	39 (100.0)		
Occupation	HCW	1377 (99.0)	14 (1.0)	0.708

	N-HCW	567 (99.3)	4 (0.7)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.527
	6-15	525 (99.4)	3 (0.6)	
	≥16	1320 (99.0)	14 (1.0)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Efficacy		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.674
	36-55	1047 (98.7)	14 (1.3)	
	56-75	806 (98.8)	10 (1.2)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1449 (98.9)	16 (1.1)	0.772
	M	478 (98.8)	6 (1.2)	
	N.D.	39 (100.0)		
Occupation	HCW	1375 (98.8)	16 (1.2)	0.617
	N-HCW	562 (98.4)	9 (1.6)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.689
	6-15	522 (98.9)	6 (1.1)	
	≥16	1319 (98.9)	15 (1.1)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Safety		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.295
	36-55	1047 (98.7)	14 (1.3)	
	56-75	799 (97.9)	17 (2.1)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1444 (98.6)	21 (1.4)	0.454
	M	474 (97.9)	10 (2.1)	
	N.D.	39 (100.0)		
Occupation	HCW	1369 (98.4)	22 (1.6)	0.792
	N-HCW	562 (98.4)	9 (1.6)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.545
	6-15	521 (98.7)	7 (1.3)	
	≥16	1313 (98.4)	21 (1.6)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Effective		Not missing	Missing	<i>p</i>
Age	20-35	99 (99.0)	1 (1.0)	0.931
	36-55	1053 (99.2)	8 (0.8)	
	56-75	808 (99.0)	8 (1.0)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1456 (99.4)	9 (0.6)	0.332

	M	478 (98.8)	6 (1.2)	
	N.D.	39 (100.0)		
Occupation	HCW	1378 (99.1)	13 (0.9)	0.868
	N-HCW	566 (99.1)	5 (0.9)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.464
	6-15	525 (99.4)	3 (0.6)	
	≥16	1319 (98.9)	15 (1.1)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Safe		Not missing	Missing	<i>p</i>
Age	20-35	100 (100.0)	0 (0.0)	0.879
	36-55	1055 (99.4)	6 (0.6)	
	56-75	812 (99.5)	4 (0.5)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1458 (99.5)	7 (0.5)	0.840
	M	481 (99.4)	3 (0.6)	
	N.D.	39 (100.0)		
Occupation	HCW	1381 (99.3)	10 (0.7)	0.310
	N-HCW	570 (99.8)	1 (0.2)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.785
	6-15	526 (99.6)	2 (0.4)	
	≥16	1326 (99.4)	8 (0.6)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Updated		Not missing	Missing	<i>p</i>
Age	20-35	99 (99.0)	1 (1.0)	0.446
	36-55	1056 (99.5)	5 (0.5)	
	56-75	807 (98.9)	9 (1.1)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1454 (99.2)	11 (0.8)	0.831
	M	481 (99.4)	3 (0.6)	
	N.D.	39 (100.0)		
Occupation	HCW	1376 (98.9)	15 (1.1)	0.112
	N-HCW	570 (99.8)	1 (0.2)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	107 (100.0)	0 (0.0)	0.354
	6-15	526 (99.6)	2 (0.4)	
	≥16	1320 (99.0)	14 (1.0)	
	N.D.	22 (100.0)	0 (0.0)	

Missing data analysis: Booster Dose		Not missing	Missing	<i>p</i>
Age	20-35	99 (99.0)	1 (1.0)	0.978
	36-55	1049 (98.9)	12 (1.1)	

	56-75	807 (98.9)	9 (1.1)	
	N.D.	16 (100.0)	0 (0.0)	
Gender	F	1447 (98.8)	18 (1.2)	0.612
	M	480 (99.2)	4 (0.8)	
	N.D.	39 (100.0)		
Occupation	HCW	1377 (99.0)	14 (1.0)	0.779
	N-HCW	564 (98.8)	7 (1.2)	
	N.D.	29 (100.0)	0 (0.0)	
Seniority	1-5	106 (99.1)	1 (0.9)	0.820
	6-15	521 (98.7)	7 (1.3)	
	≥16	1322 (99.1)	12 (0.9)	
	N.D.	22 (100.0)	0 (0.0)	